Habits

EU Herbal Smoking Products with Nicotine Regulatory Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 16, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Electronic cigarettes, Cigarettes, Smoking cessation, Nicotinic agonists, Habits, Alkaloids found in Erythroxylum coca, Nicotine, Cigarette, Smoking, Electronic cigarette

The "Regulatory Report: EU Regulation of Herbal Smoking Products with Nicotine" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: EU Regulation of Herbal Smoking Products with Nicotine" report has been added to ResearchAndMarkets.com's offering.
  • This report analyses EU member states' interpretation of herbal smoking products containing nicotine, which are not explicitly regulated at the EU level.
  • It also provides an overview of the regulations that apply to herbal products for smoking, regardless of whether they contain nicotine.
  • The products to be analysed in this report are herbal nicotine products or so-called non-tobacco cigarettes, which are composed of a mixture of various herbs plus nicotine.

DoSomething.org and Campaign for Tobacco-Free Kids Encourages Gen Z to Fight Tobacco Use as a Social Justice Issue

Retrieved on: 
Tuesday, July 13, 2021
Psychoactive drugs, Nicotinic agonists, Habits, Entheogens, Leaves, Native American religion, Tobacco, DoSomething, Nicotine

"We are excited to join forces with the Campaign for Tobacco-Free Kids for the first time, and applaud them for their highly impactful efforts to-date," says DeNora Getachew, CEO at DoSomething.org.

Key Points: 
  • "We are excited to join forces with the Campaign for Tobacco-Free Kids for the first time, and applaud them for their highly impactful efforts to-date," says DeNora Getachew, CEO at DoSomething.org.
  • Through this program we will activate Gen Z to keep loved ones and peers tobacco-free for the betterment of people and our planet."
  • "Through this program, I've learned that nicotine and tobacco use impact more than just your physical health.
  • It's estimated that Big Tobacco spends $8.2 billion every year to market its deadly and addictive products.

Pivot's Breath Sensor Receives Expanded Indications for Use from FDA

Retrieved on: 
Monday, July 12, 2021
Human behavior, Habits, Health, Health effects of tobacco, Drug rehabilitation, General practice, Smoking cessation, Food and Drug Administration, Smoking, Sensor, Tobacco smoking

As the only over-the-counter, FDA-cleared breath sensor for smoking cessation, Pivots Carbon Monoxide Breath Sensor provides innovative technology that goes beyond measuring the impact of smoking cessation: The sensor has now been proven to increase a persons motivation to quit.

Key Points: 
  • As the only over-the-counter, FDA-cleared breath sensor for smoking cessation, Pivots Carbon Monoxide Breath Sensor provides innovative technology that goes beyond measuring the impact of smoking cessation: The sensor has now been proven to increase a persons motivation to quit.
  • The new FDA clearance allows Carrot to highlight this expanded indication in its labeling and promotion of the sensor.
  • The emergence of an over-the-counter breath sensor that can help people quit tobacco is comparable to when consumer grade glucose meters became available, empowering people in their own diabetes care.
  • In the clinical trial supporting the expanded indications of the Pivot Breath Sensor, Carrot tested the device with 234 heavy tobacco users.

Worldwide Pulmonary Drugs Industry to 2026 - Rising Prevalence of Pulmonary Diseases is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Pharmaceutical, Health, Cardiology, Human behavior, Habits, Articles, Life sciences, Biotechnology, Drug culture, Smoking, Tobacco smoking, Biosimilar, Tobacco

The Global Pulmonary Drugs Market is estimated to be USD 56.9 Bn in 2021 and is expected to reach USD 67.6 Bn by 2026, growing at a CAGR of 3.5%.

Key Points: 
  • The Global Pulmonary Drugs Market is estimated to be USD 56.9 Bn in 2021 and is expected to reach USD 67.6 Bn by 2026, growing at a CAGR of 3.5%.
  • The factors that are driving the market include the rising prevalence of pulmonary diseases and the growing geriatric population.
  • With the entry of innovative drugs into the markets, there is an increased scope for market growth.
  • Government and non-government initiatives, and the availability of biosimilars, increasing tobacco smoking are fuelling the market growth.

Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation

Retrieved on: 
Wednesday, June 30, 2021
Health, FDA, Other Health, General Health, Clinical trials, Pharmaceutical, Cardiology, Psychoactive drugs, Human behavior, Smoking, Health, Health effects of tobacco, Habits, Substance dependence, Drug rehabilitation, Smoking cessation, Addiction, Tobacco smoking, Nicotine Anonymous, EMB-001, Embera NeuroTherapeutics, EMB-001, EMBERA NEUROTHERAPEUTICS

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and potentially other addictions, today announced that the first subject has been dosed in a Phase 2a smoking cessation study for the treatment of tobacco use disorder.

Key Points: 
  • Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and potentially other addictions, today announced that the first subject has been dosed in a Phase 2a smoking cessation study for the treatment of tobacco use disorder.
  • In a Phase 1 Safety study, EMB-001 was well-tolerated and signals of efficacy were observed.
  • This Phase 2a study will help us better understand the efficacy of EMB-001 in helping subjects stop smoking.
  • Current investors in Embera participated in a $1.3 million financing to support the EMB-001 Phase 2a tobacco use disorder clinical study.

Canada’s proposed flavour ban will harm public health

Retrieved on: 
Friday, June 18, 2021
Human behavior, Tobacco, Habits, Psychoactive drugs, Drug culture, Smoking, Electronic cigarettes, Smoking cessation, Health effects of tobacco

If the flavour ban is implemented, hundreds of thousands of smokers may be pushed back to smoking or to the black-market and many will die.

Key Points: 
  • If the flavour ban is implemented, hundreds of thousands of smokers may be pushed back to smoking or to the black-market and many will die.
  • Research from Yale School of Public Health finds that smokers that quit using a flavoured product are 2.5 times more likely to be successful.
  • The study concludes, While proposed flavour bans are well-intentioned, they have disastrous outcomes.
  • A flavour ban will reduce the appeal of the product and will sentence many smokers to their death.

The Tobacco and Smoking Act has squandered Nunavut’s chance to quickly reduce smoking rates

Retrieved on: 
Wednesday, June 16, 2021
Human behavior, Psychoactive drugs, Smoking, Habits, Health effects of tobacco, Health, Drug culture, Tobacco smoking, Youth smoking, Tobacco, Prevalence of tobacco use, Smoking in Australia

High tobacco use prevalence has caused Nunavut to have the highest rates of lung cancer in Canada.

Key Points: 
  • High tobacco use prevalence has caused Nunavut to have the highest rates of lung cancer in Canada.
  • Tobacco use in Nunavut remains a health crisis, with 1 in 5 deaths caused by smoking.
  • Youth smoking rates may also increase as found recently by the Yale School of Public Health Study, which tracked an increase in youth smoking rates following the flavour ban in San Francisco.
  • An opportunity to reduce smoking rates faster than previously thought possible has been squandered.

Argentina Heated Tobacco and Oral Tobacco Regulatory Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Nicotinic agonists, Electronic cigarettes, Habits, Snus, Heated tobacco product, Nicotine pouch, Chewing tobacco, Nicotine, Tobacco harm reduction, Tobacco smoking

The "Regulatory Report: Argentina - Heated Tobacco and Oral Tobacco" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: Argentina - Heated Tobacco and Oral Tobacco" report has been added to ResearchAndMarkets.com's offering.
  • The regulation of heated tobacco and modern oral products, such as tobacco-free nicotine pouches or snus containing tobacco, will remain unchanged in Argentina for the foreseeable future.
  • For the time being, it does not seem to be a priority for the authorities to establish a clear regulatory framework for heated tobacco products, which means that they will remain under the legal framework of tobacco products.
  • This initiative has already been proposed by countries such as the UK and New Zealand, which seek the same by 2030 and 2025 respectively.

Japan HNB, Oral Tobacco and Nicotine Pouches Market Regulatory Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 9, 2021
Tobacco, Retail, Psychoactive drugs, Human behavior, Habits, Tobacco, Entheogens, Native American religion, Smoking, Chewing tobacco, Snus, Regulation of tobacco by the U.S. Food and Drug Administration

The "Regulatory Report: Japan - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: Japan - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.
  • The Tobacco Business Law defines tobacco products as those entirely or partially made of tobacco leaves and made for smoking, chewing or sniffing.
  • This means that hardware used to heat tobacco is not a tobacco product, but should comply with general electronic product consumer laws.
  • The framework set out in the Tobacco Business Law and Tobacco Business Law Enforcement Regulations defines tobacco products as "entirely or partially made of tobacco leaves and made for smoking, chewing or sniffing".

Hong Kong HNB, Oral Tobacco and Nicotine Pouches Regulatory Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 9, 2021
Tobacco, Retail, Psychoactive drugs, Tobacco, Electronic cigarettes, Habits, Nicotinic agonists, Smoking cessation, Heated tobacco product, Electronic cigarette, Nicotine pouch, Cigarette, Smoking, Nicotine

The "Regulatory Report: Hong Kong - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Regulatory Report: Hong Kong - HNB, Oral Tobacco and Nicotine Pouches" report has been added to ResearchAndMarkets.com's offering.
  • Since 2019 the authorities in Hong Kong have been considering a ban on alternative smoking products such as e-cigarettes, heated tobacco and herbal sticks (tobacco-free).
  • However, Hong Kong Customs has de facto prohibited the import of heated tobacco products, by not issuing licences, suggesting an antagonistic overall policy towards reduced-risk tobacco products.
  • The current ban on oral tobacco products and the pharmaceutical classification of nicotine pouches are not expected to change in short term.